Bayer and Mammoth Biosciences today announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies
Read MoreCongratulations to Mammoth Biosciences for signing a $691M collaboration deal with Vertex→
/
Vertex Pharmaceuticals and Mammoth Biosciences today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems.
Read MoreCongratulations to Mammoth Biosciences on $195 million financing at $1 billion+ valuation, led by Redmile Group and Foresite Capital→
/
Mammoth Biosciences raises $195 million, vaulting Its CRISPR tech to unicorn status. The latest round of financing will supercharge the creation of transformative CRISPR products including ultra-small proteins for therapeutics and decentralized diagnostics.
Read MoreMammoth Biosciences collaborates with GSK Consumer Healthcare to develop at home COVID-19 test→
/
Mammoth Bioscience today announced a collaboration with GSK Consumer Healthcare to develop an accurate, easy-to-use, fully disposable, rapid and handheld test that consumers and healthcare providers in clinics can use to detect active SARS-CoV-2, the novel coronavirus that causes COVID-19.
Read MoreCongratulations to Mammoth Biosciences for raising $45M Series B, led by Decheng Capital and new investor Verily→
/
Mammoth Biosciences today announced a $45M Series B to develop the next generation of CRISPR products and help to tackle Coronavirus.
Read More
Mammoth Biosciences and Pacific 8 Ventures Keynote Speakers at Bio Medtex Conference in November 2018
/
Mammoth Biosciences and Pacific 8 Ventures Keynote Speakers at Bio Medtex Conference in November 2018
Read More
